Medicare GLP-1 Bridge Program: $50/Month: Now Live as of July 1, 2026
As of July 1, 2026, Medicare Part D beneficiaries can now get Foundayo, Wegovy, and Zepbound KwikPen at a flat $50/month copay through the Medicare GLP-1 Bridge demonstration, confirmed by CMS, NPR, and KFF. The program runs through December 31, 2027.
The $50 copay does notcount toward the Part D deductible or the $2,100 annual out-of-pocket cap. Prior authorization is required and processed through Humana (CMS's designated central processor via LI NET infrastructure).
Free 60-second check. No sign-up needed.
Does Medicare cover it? At a glance
| Drug | Covered? | How / cost |
|---|---|---|
| Zepbound (KwikPen only) $50/mo copay via Part D Bridge, July 1, 2026 to Dec 31, 2027. Vials + single-dose pens NOT covered. | Yes | $50/mo copay via Part D Bridge, July 1, 2026 to Dec 31, 2027. Vials + single-dose pens NOT covered. |
| Wegovy (injection + oral tablet) $50/mo copay via Part D Bridge, all formulations, July 1, 2026 to Dec 31, 2027. | Yes | $50/mo copay via Part D Bridge, all formulations, July 1, 2026 to Dec 31, 2027. |
| Foundayo (orforglipron) $50/mo copay via Part D Bridge, all formulations of the once-daily oral GLP-1. | Yes | $50/mo copay via Part D Bridge, all formulations of the once-daily oral GLP-1. |
| Ozempic Covered by your regular Part D plan for type 2 diabetes only. Not FDA-approved or covered for weight loss. | T2D only | Covered by your regular Part D plan for type 2 diabetes only. Not FDA-approved or covered for weight loss. |
| Compounded semaglutide / tirzepatide Not covered by the Bridge or Part D. Cash-pay only, see cheapest providers below. | No | Not covered by the Bridge or Part D. Cash-pay only, see cheapest providers below. |
Sources and full detail in which drugs are covered below. If you don't qualify, cash-pay options start around $99/mo.
Bridge enrollment alerts
Medicare GLP-1 coverage changes constantly. Get an email when Bridge enrollment rules, covered drugs, or the post-2027 outlook change.
Free. No affiliate spam. Unsubscribe in one click.
Which drugs are covered?
The at-a-glance table above gives the yes/no answer. Here's the detail on the four Bridge-covered products, including the Zepbound restriction: only the KwikPen formulation qualifies.
Source: CMS Medicare GLP-1 Bridge, NPR May 2026, KFF
Which Medicare plans qualify?
Part D sponsors do not have to opt in. The Bridge runs as a separate CMS demonstration. Any beneficiary enrolled in one of the five eligible plan types automatically has access.
How prior authorization works
Humana is the single central processor for all Bridge prior authorizations and claims adjudication. This is the same Humana infrastructure that already runs the LI NET (Low-Income Newly Eligible Transition) program for CMS.
CMS released the official prior authorization request form on June 8, 2026. It specifies a two-step sequence:
- Your pharmacy first runs a claim against the dedicated Bridge processor (BIN 028918, PCN MEDDGLP1BR) and receives a denial, that denied claim opens the prior-auth pathway.
- Your prescriber then files the CMS form electronically via CoverMyMeds or by fax. Only prescribing clinicians can submit; beneficiaries cannot self-file.
- The PA routes through Humana for central processing regardless of your specific plan. Nothing is processed before July 1, 2026.
- Once approved, you fill the prescription at any participating pharmacy at the $50 copay.
If you were already on a GLP-1 at a higher BMI and have since lost weight, the form instructs your prescriber to record your initial BMI at the time therapy started.
Where you actually fill it
Approval and access are two different problems. The Bridge bills on its own rail, so the question of which pharmacy will run that claim is a real one, and until August 2026 almost no coverage answered it.
Amazon says it now delivers Wegovy (injection and tablet), Zepbound KwikPen and Foundayo to eligible Medicare Part D patients at the $50 monthly copay, with free home delivery and no Prime membership required. It puts Same-Day Delivery in more than 3,100 US cities and towns, expanding to nearly 4,500 by the end of 2026, and says eligibility verification, prior authorization and billing are handled automatically once your clinician sends the e-prescription. Those are Amazon's figures for Amazon's own service, not a CMS statement, and the Bridge is not exclusive to any pharmacy: the $50 copay applies at any participating pharmacy that can bill the demonstration. We have seen headlines naming other national chains, but no primary confirmation, so we are not listing any others until there is one.
Source: Amazon, August 2026
- 1 Your prescriber has to certify a lifestyle program. Medicare requires the clinician to attest that the GLP-1 is being used as part of a program focused on diet and exercise. A prescription on its own is not enough.
- 2 One prior authorization covers you through December 31, 2027. It stays valid for refills and for dose changes. Switching to a different GLP-1 is what forces a new one.
- 3 You fill one month at a time. Either 28 or 30 days depending on the drug. There is no 90-day fill on the Bridge.
- 4 The $50 is money you will not get back anywhere else. Because the Bridge sits outside the Part D benefit, the copay does not touch your deductible or your out-of-pocket limit, never appears on your Part D Explanation of Benefits or your Medicare Summary Notice, cannot be reduced by Extra Help, and cannot be spread across months through the Medicare Prescription Payment Plan.
Source: Medicare.gov, Weight loss drugs, CMS Medicare GLP-1 Bridge FAQs. Verified August 10, 2026.
Who qualifies, and the comorbidity twist
- ✓ Enrolled in Medicare Part D (PDP, MA-PD, SNP, EGWP, or LI NET)
- ✓ Age 65+ OR disability via SSDI (24+ months) OR End-Stage Renal Disease
- ✓ Tier 1, BMI ≥ 35, no additional diagnosis required
- ✓ Tier 2, BMI ≥ 30 with HFpEF, uncontrolled hypertension, or CKD stage 3a+
- ✓ Tier 3, BMI ≥ 27 with pre-diabetes, prior MI, prior stroke, or symptomatic PAD
Not sure which tier you fall in? Enter your height and weight.
Rule of thumb: BMI 30+, or 27+ with a weight-related condition, generally qualifies for GLP-1 weight-management treatment.
Educational estimate only, not medical advice or a diagnosis. Your prescriber confirms eligibility. Full check: eligibility checker.
Providers to watch for the Bridge
These telehealth providers carry Bridge-covered drugs on their menus (in some cases announced as coming soon, not yet live). Useful now for a consultation, and worth watching as the Bridge rolls out.
$149/mo · 7.2/10
The official routes, and the authority CMS is using
Check eligibility and enrol through Medicare directly at Medicare.gov/glp1bridge, or call 1-800-MEDICARE (1-800-633-4227); TTY 1-877-486-2048. We are an independent comparison site and earn nothing from either.
- Your Part D plan does not have to opt in.CMS runs the Bridge outside the Part D benefit's coverage and payment flow, so sponsors carry no risk and do not have to join for you to get the drugs. If a plan tells you it does not participate, that is not a reason you cannot use the Bridge.
- One central processor handles it. For 2026 CMS uses a single central processor for prior authorisation, claims adjudication and payment to pharmacies, rather than routing through each plan.
- The legal basis is a demonstration authority, not a benefit expansion. Section 402(a)(1)(A) of the Social Security Amendments of 1967, made applicable to Part D by section 1860D-42(b) of the Social Security Act. That is why it has an end date and why the terms differ from ordinary Part D.
Quoted from the CMS Medicare GLP-1 Bridge FAQ, page last modified July 13, 2026, read August 4, 2026.
Frequently asked questions
Does the $50 copay count toward my Part D deductible?
No, and there are two further consequences CMS states plainly. Because Bridge drugs are furnished outside the Part D benefit payment flow, the Part D deductible does not apply, no part of the $50 counts toward your TrOOP (true out-of-pocket) costs, and there is no low-income subsidy provided for LIS beneficiaries. That last point matters most: if you normally get Extra Help with drug costs, it does not reduce the $50 here, so the Bridge is the same price for a low-income beneficiary as for anyone else. CMS confirmed all three on its Bridge FAQ page.
Will the $50 go up when I increase my dose?
No. The copay is flat at $50/month regardless of which dose you're on. Whether you're at the 0.25 mg Wegovy starting dose or the 2.4 mg maintenance dose, you pay $50.
Why is Zepbound KwikPen-only? What about the vials?
CMS restricted Zepbound to the KwikPen formulation for the Bridge. Single-dose vials and single-dose pens, which are often used by compounding pharmacies as reference products, are excluded. If you currently use vials, ask your prescriber about switching to KwikPen before July 1.
What does 'prior auth via Humana' mean for patients?
CMS designated Humana as the single central processor for all Bridge prior authorizations and claims, using the same LI NET infrastructure Humana already operates. In practice: your prescriber submits a prior auth the same way they submit any Part D PA. The claims then route through Humana's central processing regardless of which plan you're enrolled in.
Can I get the Bridge if I have Medicare Advantage?
Yes, if your Advantage plan includes Part D drug coverage (MA-PD). The Bridge is a CMS demonstration that runs separately from the plan, Part D sponsors don't have to opt in for their enrollees to access it.
What happens after December 31, 2027?
Unresolved, and be careful with what you read elsewhere. The BALANCE Model's Part D expansion was delayed in April 2026 rather than cancelled: CMS's own Bridge FAQ, last modified July 13, 2026, says the Bridge was extended through December 31, 2027 to let CMS collect GLP-1 utilisation data to share with Part D sponsors 'ahead of potential implementation of BALANCE in Part D'. So BALANCE is postponed and still live as a possibility. After December 2027 the options are that BALANCE arrives, CMS extends the Bridge again, Congress passes the Treat and Reduce Obesity Act, or coverage lapses. We update this page against the CMS source rather than against news coverage.